It can be difficult to balance the benefits and risks of intensive blood pressure (BP) control in older adults. Mitra Jamshidian and fellow researchers evaluated data from the multicenter, randomized, double-blind SPRINT study to determine the net benefit of intensive BP lowering (systolic BP <120 mmHg) in older patients.
Advertisement
Life-threatening hyperkalemia can be treated successfully with medical management instead of dialysis.
Researchers can quantify absorbed doses through serial postinfusion scintigraphy measurements of the γ-emissions.
Two years after its approval, researchers studied the use of finerenone in adults with type 2 diabetes and CKD.
The primary end point of the RESILIENT trial was OS.
Breast cancer survivors have a modestly increased risk of type 2 diabetes, largely driven by breast cancer treatment.
Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer.
Long- and short-term use of SZC were compared to assess their association with rates of hyperkalemia-related hospitalization.
Patients with breast cancer who have high levels of glycosylated hemoglobin have an increased risk of recurrence and death.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Researchers can quantify absorbed doses through serial postinfusion scintigraphy measurements of the γ-emissions.
Dr. Yarchoan details neoantigen-specific T cell responses assessed in the study.
Determining which patients can benefit the most from immunotherapy remains elusive.
Researchers used descriptive statistics to analyze first-line treatment patterns.
Dr. Sethi continues his comments on NER deficiency in gastric cancer cell lines in response to cisplatin treatment.
Dr. Sethi discusses homologous recombination and nucleotide excision repair pathways in DNA repair for cancers.
The Latest From Heme Today
Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.
Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.
Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.
The gene therapy, which costs $3.1 million, was approved by the FDA in December 2023.
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
